Searchable abstracts of presentations at key conferences in endocrinology

ea0056p135 | Endocrine tumours and neoplasia | ECE2018

Multiple endocrine neoplasia type 1: a retrospective monocenter analysis of 73 cases

Modica Roberta , Lo Calzo Fabio , de Cicco Federica , Bottiglieri Filomena , Sciammarella Concetta , Colao Annamaria , Faggiano Antongiulio

Multiple endocrine neoplasia type 1 (MEN1) is an inherited syndrome, affecting multiple endocrine glands whose natural history remains largely unknown. Aim of this study was to assess the epidemiological and clinical profile of MEN1 in a single center. Seventy-three MEN1 patients, belonging to 30 different families, referred at the NET Center of Naples, from 2000 to 2017, were evaluated. Male/female ratio was 0.73, mean age 43 years (range 10–86). Forty-six cases (64%) we...

ea0073aep22 | Adrenal and Cardiovascular Endocrinology | ECE2021

Impact of adrenal insufficiency on female sexual function: A preliminary study

Zamponi Virginia , Mazzilli Rossella , Maggio Roberta , Lardo Pina , Olana Soraya , Pugliese Giuseppe , Faggiano Antongiulio , Stigliano Antonio

IntroductionAdrenal insufficiency is a clinical condition that leads to depletion of glucocorticoids, mineralocorticoids and androgens. While in men adrenal androgen deficiency is not clinically significant for testicular testosterone synthesis, in women so far androgen treatment is suggested for the reduction of libido and depression. However, no data is currently available on female sexual function.Primary endpoints<p class="...

ea0063p440 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Neuroendocrine neoplasms (NEN) arising in uncommon sites: epidemiological and clinical features

Modica Roberta , de Cicco Federica , Bottiglieri Filomena , Di Maio Silvana , Altieri Barbara , Rainone Carmen , Faggiano Antongiulio , Colao Annamaria

Background and aim: Neuroendocrine neoplasms (NEN) show increasing incidence and varying biology, but epidemiological and clinical data for other than gastroenteropancreatic (GEP) and thoracic NEN are scattered. Furthermore the best therapeutic approach in NEN arising in uncommon sites is still debated. Aim of this study is to assess the epidemiological and clinical features of NEN arising in uncommon sites in a monocentric series of a referral center.Ma...

ea0063p453 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a case-control study from NETTARE Unit

Feola Tiziana , Sesti Franz , Puliani Giulia , Sbardella Emilia , Cozzolino Alessia , Lenzi Andrea , Faggiano Antongiulio , Isidori Andrea M , Giannetta Elisa

Introduction: GEP-NENs represent a heterogeneous group of neoplasms with increasing incidence in the last years. Pathogenesis and risk factors of sporadic GEP-NENs are not clear and still debated. The aim of this study is to evaluate the main risk factors for sporadic GEP-NENs in patients followed by the NETTARE Unit (NeuroEndocrine TAsk force of of ‘Sapienza’ University of Rome).Methods: We performed a case-control study including 32 consecuti...

ea0070aep718 | Pituitary and Neuroendocrinology | ECE2020

Evaluation of early predictors of metabolic syndrome in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Bottiglieri Filomena , Modica Roberta , Barrea Luigi , de Cicco Federica , Minotta Roberto , Muscogiuri Giovanna , Savastano Silvia , Faggiano Antongiulio , Colao Annamaria

Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking. Aim of this study was to explore the association of early predictors of MetS with GEP-NET, usingas tools Fatty Liver Index (FLI), a predictor of non-alcoholic fatty liver disease (NAFLD)and Visceral Adiposity Index (VAI), a gender-specific indicator of adipose dysfunction. A cross-sectional case-control observational study was conducted. VA...

ea0022p405 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Cinacalcet hydrochloride effectively controlled primary hyperparathyroidism in patients unresponsive to bisphosphonates

Faggiano Antongiulio , Somma Carolina Di , Milone Francesco , Ramundo Valeria , Rota Francesca , Vuolo Laura , Guerra Ermelinda , Colao Annamaria

Context: Until now the role of medical therapy in patients with primary hyperparathyroidism (PHP) was mainly based on the use of bisphosphonates. Recently, cinacalcet hydrochloride was reported to be effective in control hypercalcemia in PHP. The aim of this study was to evaluate the efficacy of cinacalcet in PHP patients who were not effectively controlled with alendronate.Patients and methods: Fourteen PHP patients (mean age 64.1±2.6) were include...

ea0073aep575 | Reproductive and Developmental Endocrinology | ECE2021

Erectile dysfunction as a marker of newly diagnosed endocrine and metabolic disorders

Mazzilli Rossella , Zamponi Virginia , Olana Soraya , bollanti lucilla , Mikovic Nevena , Napoli Angela , Conti Francesco , Pugliese Giuseppe , Faggiano Antongiulio

AimThe aim of this study was to evaluate: a) the prevalence of a previously unknown endocrine / metabolic dysfunction, namely hypogonadism, thyroid dysfunction, hyperprolactinemia, and diabetes or prediabetes, in a population of patients affected by Erectile Dysfunction (ED); b) the differences in ED severity according to the presence/absence of specific endocrine / metabolic dysfunctions.Material and Methods...

ea0081p388 | Endocrine-Related Cancer | ECE2022

Endocrine-metabolic disorders in patients with gastroenteropancreatic and lung neuroendocrine tumors

Zamponi Virginia , Mazzilli Rossella , Russo Flaminia , Mikovic Nevena , Rinzivillo Maria , Magi Ludovica , Trabalza Marinucci Beatrice , Siciliani Alessandra , Panzuto Francesco , Faggiano Antongiulio

Background: Neuroendocrine tumors (NETs) are characterized by long survival and slow progression. In the clinical practice adifferent types of endocrine-metabolic disorders can occur. Such disorders are either comorbidities related to the neoplasm or side effects of specific oncological treatments. The aim of this study is to evaluate type and prevalence of the endocrine-metabolic disorders in patients with gastroenteropancreatic (GEP) and lung NETs.Mate...

ea0081p390 | Endocrine-Related Cancer | ECE2022

Uncovering the immune profile in well-differentiated gastroenteropancreatic neuroendocrine tumors

Sesti Franz , Puliani Giulia , Sciarra Francesca , Feola Tiziana , Centello Roberta , Di Vito Valentina , Pandozzi Carla , Lenzi Andrea , Isidori Andrea , Venneri Mary Anna , Faggiano Antongiulio , Giannetta Elisa

Introduction: Immune tumor microenvironment plays a key role in tumors’ growth and metastatic spread, while its role in the heterogeneous field of neuroendocrine neoplasms (NENs) remains unclear. There is evidence that tumor progression in NENs is promoted by an immunosuppressed microenvironment created by a plethora of infiltrating immune cells. Changes in circulating leukocyte and peripheral blood mononuclear cell (PBMC) subpopulations can mirror the local alteration of...

ea0063gp2 | Adrenal and Neuroendocrine - Tumour | ECE2019

Lanreotide therapy vs wait-and-see in patients with pancreatic neuroendocrine tumors

Faggiano Antongiulio , Modica Roberta , Calzo Fabio Lo , Camera Luigi , Napolitano Vincenzo , Altieri Barbara , De Cicco Federica , Bottiglieri Filomena , Sesti Franz , Isidori Andrea M. , Colao Annamaria

Background & Aim: Pancreatic neuroendocrine tumors (pNETs) are detected in >80% of MEN1 patients. MEN1 pNETs are well differentiated G1-G2 NETs. They are usually not surged unless a size >1–2 cm or a growth rate >0.5 cm per year. Somatostatin analogues represent one of the main therapeutic option in patients affected with G1-G2 NETs. However, neither somatostatin analogues nor other therapies have been prospectively evaluated in clinical trials specificall...